Abbott Park, Illinois, December 18, 2025 — Abbott has secured U.S. Food and Drug Administration (FDA) clearance and CE Mark approval for its Amplatzer Piccolo™ Delivery System, a purpose-built medical device designed specifically for premature infants with patent ductus arteriosus (PDA), a potentially life-threatening congenital heart defect. The newly approved delivery system is used with Abbott’s Amplatzer Piccolo Occluder and enables safer, more precise minimally invasive PDA closure procedures in some of the smallest and most fragile patients, including infants weighing as little as two pounds.
Science Significance
From a scientific and engineering perspective, the Amplatzer Piccolo Delivery System represents a significant advancement in neonatal interventional cardiology. PDA closure in premature infants presents unique anatomical and physiological challenges due to extremely small blood vessels, fragile cardiac structures, and heightened procedural risk. The newly cleared system incorporates a shorter, softer, single-catheter design, allowing physicians to precisely position the Piccolo Occluder with improved control and reduced trauma. This innovation builds on Abbott’s prior breakthrough with the world’s smallest transcatheter heart device, advancing the science of miniaturized, patient-specific cardiovascular technologies.
Regulatory Significance
The dual achievement of FDA clearance in the United States and CE Mark approval in Europe underscores the delivery system’s robust safety, performance, and quality profile. Regulatory authorization confirms that the device meets stringent international standards for medical device design, manufacturing, and clinical use, particularly in a vulnerable pediatric population. Importantly, the clearance expands the approved ecosystem surrounding the Amplatzer Piccolo Occluder, which itself received regulatory approvals in 2019, reinforcing confidence in Abbott’s end-to-end regulatory strategy for pediatric structural heart devices.
Business Significance
Advertisement
Strategically, this milestone strengthens Abbott’s leadership in the global structural heart and pediatric medical device market. By offering the first and only delivery system designed exclusively for premature infants with PDA, Abbott further differentiates its portfolio in a specialized but clinically critical segment. The approval enhances procedural efficiency for hospitals, reinforces long-term physician adoption, and complements Abbott’s broader pediatric cardiac portfolio, including miniaturized heart valves and mechanical circulatory support systems. This positions Abbott for sustained growth as demand rises for high-precision, minimally invasive therapies.
Patients’ Significance
For patients and families, the impact is profound. Approximately 20% of premature infants develop a PDA requiring treatment, and traditional surgical approaches can carry significant risks. The Amplatzer Piccolo Delivery System enables minimally invasive closure, reducing the need for open surgery, shortening recovery times, and lowering the risk of complications. By allowing greater procedural confidence and accuracy, the system improves outcomes for one of the most vulnerable patient populations in modern medicine, offering premature babies a safer path toward healthy cardiac development.
Policy Significance
At a policy level, the approval aligns with broader healthcare priorities focused on improving neonatal outcomes, reducing invasive surgical interventions, and advancing innovation in pediatric care. Devices specifically designed for infants address long-standing gaps in medical technology, supporting health systems’ goals of equitable, age-appropriate treatment solutions. The clearance may also encourage future investment and regulatory support for pediatric-first medical device development, an area historically underserved due to technical and economic challenges.
With FDA clearance and CE Mark approval now secured, Abbott’s Amplatzer Piccolo Delivery System sets a new benchmark in pediatric cardiac care, combining advanced engineering, regulatory rigor, and patient-centric design. The innovation reinforces Abbott’s commitment to lifesaving technologies for the youngest patients and highlights the growing role of specialized medical devices in transforming neonatal and congenital heart treatment worldwide.
Source: Abbott press release
